Genome-wide identification of chemosensitive single nucleotide polymorphism markers in colorectal cancers

Cancer Science

Volumn 101, Issue 4, 2010, Pages 1007-1013

  Kim, Jin C ^a,b   Kim, Seon Y ^b,c   Cho, Dong H ^a,b   Roh, Seon A ^a,b   Choi, Eun Y ^a,b   Jo, Yoon K ^a,b   Jung, Sang H ^a,b   Na, Young S ^b   Kim, Tae W ^b   Kim, Yong S ^b,c  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ADULT; AGED; AJAP1 GENE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CELL DEATH; CELL VIABILITY; CHEMOSENSITIVITY; COLORECTAL CANCER; CYTOTOXICITY; DISEASE CONTROL; DISEASE FREE SURVIVAL; DPYD GENE; EPHA7 GENE; ERCC4 GENE; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOME ANALYSIS; GPC5 GENE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; OR5AC2 GENE; OR5H1 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SSTR4 GENE; SULT1C2 GENE; SULT1C4 GENE; TNFRSF11B GENE; TUMOR RECURRENCE; ADJUVANT CHEMOTHERAPY; COHORT ANALYSIS; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; VALIDATION STUDY;

AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE FREQUENCY; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77957280764     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01461.x     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Shin HR, Jung KW, Won YJ et al. National cancer incidence for the year 2002 in Korea. Cancer Res Treat 2007; 39: 139-49.
3. Kelly C, Cassidy J. Chemotherapy in metastatic colorectal cancer. Surg Oncol 2007; 16: 65-70.
4. Sabharwal A, Kerr D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Rev Anticancer Ther 2007; 7: 477-87.
5. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007; 74: 659-71.
6. Waldenmaier DS, Babarina A, Kischkel FC. Rapid in vitro chemosensitivity analysis of human colon tumor cell lines. Toxicol Appl Pharmacol 2003; 192: 237-45.
7. Braun MS, Quirke P, Seymour MT. Molecular markers of chemotherapeutic response and toxicity in colorectal cancer. Expert Rev Anticancer Ther 2007; 7: 489-501.
8. Dan S, Tsunoda T, Kitahara O et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002; 62: 1139-47.
9. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci USA 2004; 101: 11809-14.
10. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet 2003; 4: 937-47.
11. Huang RS, Duan S, Shukla SJ et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007; 81: 427-37.
12. Ge D, Zhang K, Need AC et al. WGAViewer: software for genomic annotation of whole genome association studies. Genome Res 2008; 18: 640-3.
13. Kim JC, Kim DD, Lee YM et al. Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis 2009; 24: 209-18.
14. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 1987; 84: 5029-33.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000; 92: 205-16.
16. Nagasaka T, Sasamoto H, Notohara K et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004; 22: 4584-94.
17. Schulz C, Boeck S, Heinemann V, Stemmler HJ. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Schulz C, Boeck S, Heinemann V, Stemmler HJ Anticancer Drugs 2009; 20: 867-79.
18. Meng H, Tanigawa N, Hao CY, Dai DJ, Lu CD, Ji JF. Chemoresponse to docetaxel correlates with expression of the survivin splicing variants in patients with gastric cancer. Hepatogastroenterology 2007; 54: 1934-40.
19. Owatari S, Akune S, Komatsu M et al. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res 2007; 67: 4860-8.
20. Xu J, Turner A, Little J, Bleecker ER, Meyers DA. Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error? Hum Genet 2002; 111: 573-4.
21. Williamson D, Selfe J, Gordon T et al. Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res 2007; 67: 57-65.
22. Augenlicht LH, Wadler S, Corner G et al. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 1997; 57: 1769-75.
23. Xu Y, Bruno JF, Berelowitz M. Characterization of the proximal promoter region of the rat somatostatin receptor gene, SSTR4. Biochem Biophys Res Commun 1995; 206: 935-41.
24. Davies BR, Logie A, McKay JS et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmaco-kinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007; 6: 2209-19.
25. Kreienkamp HJ, Roth A, Richter D. Rat somatostatin receptor subtype 4 can be made sensitive to agonist-induced internalization by mutation of a single threonine (residue 331). DNA Cell Biol 1998; 17: 869-78.
26. Pasquale EB. Eph receptor signalling casts a wide net on cell behavior. Nat Rev Mol Cell Biol 2005; 6: 462-75.
27. Wang J, Kataoka H, Suzuki M et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 2005; 24: 5637-47.
28. Nakanishi H, Nakamura T, Canaani E, Croce CM. ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias. Proc Natl Acad Sci USA 2007; 104: 14442-7.
29. Wang X, Li M, Wang J et al. The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. Biochem Pharmacol 2006; 71: 1540-50.
30. Lipton A, Ali SM, Leitzel K et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002; 8: 2306-10.
31. Secchiero P, Corallini F, Rimondi E et al. Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood 2008; 111: 1287-94.